Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Selected highlights from CMSC 2023

June 6, 2023

…MRI in the diagnosis and management of MS; the most recent are the MAGNIMS-CMSC-NAIMS recommendations (Wattjes et al. Lancet Neurol 2021;20:653-670). In 2020, the British Columbia Medical Imaging Advisory Committee recommended the adoption of an earlier iteration (Traboulsee et al. AJNR Am J Neuroradiol 2016;37:394-401) province-wide. A survey in 2022 found that only 53.8% of MRI centres were fully compliant with the guidelines (Li et al. CMSC 20…

NfL – a guide to use in MS practice

May 31, 2023

…61:1140-1149. Free full text at www.degruyter.com/document/doi/10.1515/cclm-2023-0036/html). Although NfL levels are about 50-fold higher in CSF than in blood, blood sampling is generally preferred to avoid lumbar puncture. Single-molecule array (Simoa), which enables detection of individual NfL molecules, has greater analytical sensitivity than ELISA or electrochemiluminescence (ECL) methods (Kuhle et al. Clin Chem Lab Med 2016;54:1655-1661). The…

AAN update on anti-CD20 agents: long-term data

May 10, 2023

…data that were presented. Ocrelizumab Following the publication of the five-year data for ocrelizumab (Hauser et al. Neurology 2020;95:e1854-1867), long-term analyses of ocrelizumab have largely focused on the subgroup of previously untreated MS patients. Seven-year results were presented at ECTRIMS 2022 (Cerqueira et al. ECTRIMS 2022;P723); nine-year results were presented this year (Cerqueira et al. AAN 2023;S46.002). Overall, 67% of ocrelizumab…

Emerging role of CHI3L1 as MS biomarker

May 2, 2023

…8:e906), and with the formation of paramagnetic rim lesions (PRLs) in CIS (Comabella et al. Mult Scler 2022;28:71-81). Interestingly, PRLs were not associated with glial fibrillary acidic protein (GFAP) in serum or CSF, suggesting that CHI3L1 and GFAP reflect somewhat different aspects of MS pathophysiology. CHI3L1 can provide complementary information to serum neurofilament-light chain levels. In a study of 157 RRMS and PMS patients, RRMS patient…

AAN 2023 HIGHLIGHTS – WEDNESDAY, APRIL 26

April 26, 2023

…fying therapy. Data were collected in the period 2008 to 2022 and aquaporin-4 (AQP4-IgG) antibody testing may not have been available or routinely used during part of the observation period. sNfL after menopause Serum neurofilament-light chain levels appear to increase after menopause, according to a UCSF longitudinal study of 186 postmenopausal women with MS (Silverman et al. AAN 2023; S9.009). Median age at menopause was 52 years; median duratio…